💸 The Tape

Congress bought the hemp industry a month. It turns out that isn't enough time to do anything except panic more slowly. MJBizDaily's Margaret Jackson checked in with operators across the intoxicating hemp sector this week and found a market that is already unwinding ahead of a ban that hasn't taken effect — cutting production, culling SKUs, planning in 30-day increments and, in some cases, quietly leaving the category altogether.

Why a delay doesn't save anyone

The problem is the mismatch between a 29-day extension and how physical goods actually get made. Dylan Raap, founder of Vermont's Upstate Elevator, laid it out: raw materials are ordered months ahead, a co-packer's beverage line needs 90 days of lead time, and packaging runs are quoted in quarters, not weeks. "Nothing operates on a 29-day cycle," he told MJBiz — and so the effects of the ban are being felt before the ban exists. Raap's conclusion is the harshest in the piece: for his hemp THC business, compliance doesn't mean making the product differently. It means not making it at all.

Florida's Torch Drinks is taking the middle path, slowing hemp production, drawing down inventory and prepping a line of functional beverages with no hemp in them. Las Vegas-based Kick Beverage is the outlier, launching a new 10 mg canned product in October on the theory that a small operator using co-packers on demand doesn't carry the inventory risk that kills bigger players. Even Kick, though, says retailers and distributors have gone cold — they see the category as unpredictable and don't want to build shelf space around it.

Multiply those decisions across a sector that Whitney Economics pegs at $38.7 billion in sales and 225,000 jobs this year and you get a demand shock that shows up in Q4 regardless of what Congress does in December. Raap's point about "the whole wellness category" is the one the licensed cannabis lobby tends to skip past: the statute doesn't just kill THC gummies; it takes full-spectrum CBD tinctures, topicals and pet products off the shelf with them.

Where the ban actually sits

The mechanics matter, so here they are. The hemp redefinition was written into the November 2025 appropriations package that ended last fall's government shutdown. It replaces the 2018 Farm Bill's delta-9 threshold with a total THC standard and caps finished products at 0.4 milligrams of THC per container — a number that renders essentially every intoxicating hemp product on the market, and most non-intoxicating full-spectrum ones, "marijuana" under federal law. The original effective date was November 12, 2026.

On September 2, President Trump signed H.R. 6500, a continuing resolution funding the government through December 11, which also pushed the hemp effective date to December 11. The Senate passed it 90-6 after tabling a Ted Budd amendment to strip the hemp language; the House followed 370-48. The White House requested the delay so the industry could lobby for regulation instead of prohibition, but the administration has also said there will be no further extensions. Thirty-five state attorneys general wrote congressional leaders in August urging them to reject any attempt to weaken or delay the 2025 restrictions, and the licensed cannabis trade groups are on the same side of that letter.

One wrinkle: the delay is written into the CR rather than as a standalone date. It lasts as long as the CR does. That means the hemp question comes back to the floor on December 11 attached to must-pass funding legislation, in a lame-duck session, roughly five weeks after the midterms.

One wrinkle: the delay is written into the CR rather than as a standalone date. It lasts as long as the CR does. That means the hemp question comes back to the floor on December 11 attached to must-pass funding legislation, in a lame-duck session, roughly five weeks after the midterms.

What happens next

There are three outcomes, and they're not equally likely.

The first is a regulatory framework that replaces the ban. Several bills exist: James Comer's package pairing a longer delay with packaging, testing and age-21 rules; Van Duyne and Landsman's bill to tax and regulate hemp beverages like alcohol; a Senate companion expected from Sheehy and Klobuchar. None has cleared a committee. Writing a national cannabinoid regulatory regime from a standing start in fourteen weeks, through a Congress that couldn't pass a Farm Bill because of a SNAP dispute, is a heavy lift. The Hemp Beverage Alliance's Chris Lackner reads the delay as a signal that Washington "wants to regulate, not prohibit." That may be true of the White House. It is not obviously true of the Senate Agriculture Committee.

The second is another extension, folded into whatever December funding vehicle emerges. This is the path of least resistance and the one the administration says it won't take. Given that the last extension was also something the White House initially didn't want, treat that with appropriate skepticism — but a lame-duck Congress punting to the next one is the most probable form this takes, and each punt keeps the supply chain in the state Raap describes.

The third is implementation as written on December 11. If that happens, the intoxicating hemp market becomes a federal enforcement question overnight, the beverage category that craft brewers and distributors spent two years building goes dark in interstate commerce, and the licensed cannabis industry inherits whatever share of those consumers it can reach through dispensaries. Minnesota's regulated market, which has been fighting a $200 million hemp channel for a year, would be the first place to see the shift.

The read

The most useful sentence in the MJBiz piece is Raap's: "I'll take hope over the alternative." That is where the hemp industry is — hoping a framework materializes in a lame duck, while behaving as if it won't. Operators are reformulating into kava, kanna and non-cannabinoid functional products because that's the only plan that works under every scenario. Capital is leaving the category because no lender writes a 90-day inventory line against a 29-day policy horizon.

For licensed cannabis, the strategic question is whether to keep fighting for the ban or accept a beverage carve-out in exchange for a total-THC standard that actually gets enforced. For hemp, the question is whether the industry can produce a bill Congress can pass in a lame duck. And for both, December 11 is now a date certain — unless it isn't.

📈 Dog Walkers

$TSNDF ( ▲ 0.53% ) Expands In NJ

TerrAscend (TSX: TSND) (OTCQX: TSNDF) closed its deal for Aunt Mary's Dispensary in Flemington, New Jersey on Wednesday, giving the company its fifth retail location in the state and its second Hunterdon County store in nine months. Union Chill closed in December; Aunt Mary's now sits a few miles down the road.

The structure is the interesting part. Total consideration is US$9 million: a US$3 million five-year unsecured convertible debenture at 6% for an option on 35% of the business, plus US$6 million in cash on exercise. That's not how most MSOs buy stores. It's how you buy one in New Jersey, where the regulatory framework limits how many licenses one entity can hold outright but explicitly encourages investment in diversely owned businesses. TerrAscend is threading that needle — consolidating the economics now, taking ownership as conditions allow — and this is the second time it has done so in a year. Call it a template.

The economics work on their own. Aunt Mary's generates more than US$10 million in annualized revenue and is accretive on day one, before TerrAscend pushes Kind Tree, Legend, Valhalla and Cookies through the shelf and captures the wholesale margin on its own product. At roughly 0.9x sales for a store the company can vertically integrate, the price is a reminder that single-state retail in capped Northeast markets remains cheap relative to what it produces.

Context matters here. TerrAscend exited Michigan this year to concentrate on New Jersey, Pennsylvania and Maryland, and its three Apothecarium stores already rank in New Jersey's top 25. Five stores, top-tier cultivation capacity and a growing wholesale book make it arguably the state's strongest single-market operator — which is precisely the asset any acquirer without a New Jersey position would pay up for. Jason Wild keeps adding to it one $9 million store at a time.

$MRMD ( ▼ 2.99% ) Opens 14th Thrive Dispensary

MariMed (CSE: MRMD) (OTCQB: MRMD) opens Thrive Dispensary Columbus on Thursday, converting a former bank branch on Brice Road on the city's east side into its 14th Thrive location across five states and its second in Ohio, joining Tiffin in the western part of the state.

The bank conversion is more than a real estate footnote. The building came with a drive-through window and dedicated curbside spots, and Ohio's rules let adult-use retailers use both — a contrast with Virginia's draft regulations, which bar drive-thru and curbside for new adult-use stores entirely. In a market where convenience is starting to matter more than novelty, a former bank lane is a legitimate competitive asset, and MariMed is leaning on it.

The timing makes sense. Ohio is one of the fastest-growing legal markets in the country, with July sales of $111 million, up 22% year over year, and the state's eight-store-per-entity cap means the incumbents who arrived early are still filling out their allotments rather than fighting over saturated territory. MariMed has room to run: two stores against a cap of eight, with a cultivation and processing footprint already in place to supply its Betty's Eddies, Nature's Heritage and Vibations brands through its own shelves.

The broader strategy is the one MariMed has been telling investors for two years — build retail in high-growth, limited-license markets and use it to pull through the house brands. Columbus is the state's largest city and its most competitive dispensary market, so this store is a test of whether the Thrive banner can hold its own against the RISE, Sunnyside and Zen Leaf boxes already on the east side.

For a company that has been managing a leveraged balance sheet and a pending CFO transition, a new store opening on schedule in a growing market is the kind of unglamorous execution that keeps the story intact. The lines on Brice Road Thursday morning will say whether the bank lobby was worth the retrofit.

📺 Trade To Black

Why Us, Why Now: Boris Jordan Answers Aurora Shareholders

• Curaleaf (TSX: CURA) Chairman and CEO Boris Jordan joins Trade To Black for a live AMA built for Aurora Cannabis shareholders. Curaleaf's US$4.00-per-share offer expires December 1, Aurora's board has told you to reject it, and both sides have taken the fight to the Alberta Securities Commission.
  
  Now you get to ask the bidder directly: Why Curaleaf? Why this price? What about the $5.00 cap, the debt, the ATM dispute and the mostly-stock consideration? Boris takes your questions, unfiltered.